>>> Europe : Brokers Upgrades & Downgrades - 10th of October 2024 V3(++)

>>> Up
* Air France-KLM Raised to Neutral at Oddo BHF; PT 10 euros
* AIG Raised to Overweight at JPMorgan; PT $89
* Alcon AG Raised to Neutral at Redburn; PT 78 Swiss francs
* Danske Bank Raised to Buy at ABG; PT 222 kroner (+)
* flatexDEGIRO Raised to Outperform at BNPP Exane; PT 18 euros
* Genovis Raised to Buy at Nordea; PT 28 kronor
* Kone Raised to Buy at ABG; PT 58 euros
* Lufthansa Raised to Neutral at Oddo BHF; PT 7.50 euros
* Man Group Raised to Overweight at Barclays; PT 270 pence
* MaxCyte Raised to Buy at Deutsche Bank (+)
* Nexans PT Raised to 157 euros from 132 euros at Jefferies
* Pagegroup Raised to Buy at HSBC; PT 515 pence
* Premier Foods Raised to Overweight at Barclays; PT 207 pence
* Surgical Science Sweden Raised to Buy at Carnegie (++)

>>> Down
* Aker Solutions Cut to Hold at Pareto Securities; PT 48 kroner (++)
* Anglo American Cut to Neutral at JPMorgan; PT 2,335 pence
* Assa Abloy Cut to Hold at ABG; PT 335 kronor
* AstraZeneca Cut to Hold at Intron Health; PT 120 pence
* Bechtle Cut to Neutral at Cantor; PT 40 euros
* Boliden Cut to Underweight at JPMorgan; PT 300 kronor
* Central Asia Metals Cut to Hold at Berenberg; PT 210 pence
* DFDS Cut to Hold at SEB Equities; PT 175 kroner
* EFG International Cut to Market Perform at ZKB (+)
* EQT Cut to Hold at Carnegie; PT 250 kronor (++)
* Fevertree Drinks Cut to Neutral at BNPP Exane; PT 800 pence
* Knorr-Bremse Cut to Underperform at BofA (+)
* Konecranes Cut to Reduce at OP Corporate Bank (++)
* Lululemon Cut to Hold at CFRA
* Pernod Ricard Cut to Neutral at CIC (+)
* Remy Cointreau Cut to Neutral at CIC; PT 61 euros (+)
* Ryanair Cut to Underperform at Oddo BHF; PT 17.50 euros
* Sagax Cut to Hold at SEB Equities; PT 307 kronor
* Sika cut PT to 330 (360) CHF at Barcalys - overweight (+)
* Sika cut to Underperform at BofA (+)
* SCA Cut to Neutral at BofA (+)
* Vestas Cut to Hold at Kepler Cheuvreux; PT 150 kroner (++)
* VW Cut to Reduce at AlphaValue/Baader (+)
* Wizz Air Cut to Neutral at Oddo BHF; PT 1,450 pence

>>> Initiation
* Burckhardt Rated New Neutral at Oddo BHF; PT 612 Swiss francs
* Wacker Chemie Rated New Buy at Deutsche Bank; PT 116 euros (+)

>>> Call
* AstraZeneca Downgraded at Intron Health on Near-Term Headwinds
* Burckhardt’s Valuation Reflects Prospects, Neutral at Oddo BHF
* DFDS Shares Drop as SEB Equities Models Another Soft Quarter (++)
* Lululemon Cut to Hold at CFRA on Holiday Season Inventory Issues
* Repsol Trading Update Disappoints Analysts at MS, Jefferies
* Sika Cut to Underperform as BofA Sees Challenged Growth Outlook (+)
* Vestas Dips as Kepler Cuts to Hold, Sees Risks Hampering Upside (++)

The Information : Meta Bulls Are Overvaluing Zuckerberg’s Vision

Meta Bulls Are Overvaluing Zuckerberg’s Vision


Investors may be viewing Meta Platforms’ stock through rose-tinted glasses.

The Takeaway
• Meta stock has outperformed most big tech stocks this year
• Meta is now trading at a big premium to Alphabet
• Bullish investors say they’re betting on CEO Mark Zuckerberg

Meta’s shares have soared over 70% this year, more than those of any other big tech stock except Nvidia, giving Meta a premium valuation next to comparable stocks such as Alphabet’s. Shares of the Facebook and Instagram parent now trade at 14.2 times next year’s expected earnings before interest, taxes, depreciation and amortization, compared to 12.3 for Alphabet, according to Koyfin data. In late August, both stocks were trading at around 12.6 times.

The rally doesn’t make much sense. Meta, like Alphabet and other big tech companies like Microsoft, is pouring tens of billions into generative artificial intelligence. Alphabet and Microsoft are both charging businesses for access to their AI technology through their cloud units. Meta doesn’t have that opportunity, and it’s unclear how it will make money from the new technology.

Investors may be trusting Zuckerberg’s long-term vision that high-tech mixed reality hardware such as glasses or headsets will eventually replace the smartphone. That’s a long term vision and the company faces a lot of near term risks.

To be sure, Meta is making progress in the new-fangled technology—but these are baby steps. Ray-Ban smart glasses, which allow people to make phone calls and take photos and which incorporate Meta’s AI assistant, is the best example of the progress. Meta has had trouble keeping up with the demand for the glasses, although their overall sales are tiny compared to other devices. IDC estimates Meta shipped just 700,000 pairs, a fraction of the 26 million Apple Watches shipped in the first nine months of last year.

Zuckerberg also won plaudits for his unveiling last month of an augmented reality glasses prototype called Orion that overlay digital information onto the user’s surroundings. Those glasses represent a big part of Zuckerberg’s efforts to extend Meta’s lead in mixed reality, which it has been building through its Quest headsets. But the Orion glasses are still years away from commercial release.

Meta’s Challenges

At the same time, investors are underestimating the risks Meta faces. For one thing, while it leads the market for smart glasses now, that may not last. Google is planning its own smart glasses in collaboration with Samsung. Apple has been reported to be working on a version of smart glasses. And given Apple’s brand name and strength in consumer marketing, the company would likely pose a serious threat to Meta if it jumps into the smart glasses market.

Moreover, the expansion of the technology in smart glasses and virtual reality is enormously expensive. Both areas are part of Meta’s Reality Labs unit, which has lost roughly $60 billion cumulatively since 2019. Even if Meta’s smart glasses and VR headsets continue to sell well, there’s no guarantee the company will earn a decent return on its investment.

Abdullah Al-Rezwan, founder of equity research provider MBI Deep Dives, says that Meta accounts for nearly a third of his investment portfolio. But he says he wouldn’t buy more shares at the current price, citing “shades of concern” lurking for the company such as losses at Reality Labs.

Another set of issues he worries about are the antitrust enforcement threats facing Meta from regulators across the globe, including in the U.S. and Europe, that if successful could bring enormous consequences—such as a forced divestiture of Instagram or WhatsApp.

Al-Rezwan doesn’t mention yet another risk: the growing pressure on social media firms from lawmakers, regulators and parents to protect children and young people on the platforms from a variety of dangers. Meta faces a flood of lawsuits over those issues, as well as a growing number of state laws requiring it to take stronger action.

The company has gradually tightened controls over how children under 16 can use Instagram. The business risk is that these restrictions could deter young people from using its apps in the long term, and in the short term they could reduce the amount of time youth spend on the app, which advertisers might see as a negative.

Perhaps the biggest question mark for Meta is whether it can earn a return from the massive bet that generative AI will turbocharge its business. Meta is spending a small fortune to build out the computing infrastructure needed to run AI models. Meta Chief Financial Officer Susan Li told investors on an earnings call in July that the company expects that outlay, which it projects will be as large as $40 billion in 2024, to increase in 2025 to support further AI research and product development.

Meta bulls think the company will eventually take market share away from Alphabet in digital advertising by luring users away from Google search and to Meta’s chatbots.

“I think excitement is forming, or at least for some investors like myself, that Meta can get more of the Google pie in a way, because [with Meta AI] you have high-intent searches, which Meta normally didn’t have [before] because people were mostly just scrolling through content” on its apps, said Rihard Jarc, chief investment officer of New Era Funds.

It may not be that simple, though: Google is racing to defend its turf, and has recently started incorporating ads into some of the AI-generated summaries that now show up in response to searches conducted on its website.

Jarc is also bullish about Meta’s mixed reality prospects. Jarc reckons that Meta debuted the Orion glasses recently with the intention to signal to investors that it had an impressive product to show for its massive spending, one “we haven’t seen in the last 10 or 20 years.”

Assuming a version of Orion eventually becomes available for purchase, Meta might have a chance to control the main computing platform of the next generation, as long as people ultimately buy into the idea of using wearable devices and glasses instead of phones. But it’s far too early to know whether that world is really coming.

Even some Meta bulls aren’t too sure about that argument. As Al-Rezwan put it, “The reality is, Meta’s business is built on Apple's platform and will continue to be built on Apple platform for the foreseeable future, if not for forever.”

In the meantime, investors looking to buy Meta shares need to have complete faith that Zuckerberg’s bold swing will end up landing. In the absence of many concrete results to tout, his storytelling abilities and skillfully articulated vision have certainly helped set him apart.

>>> Pfizer: Starboard Value issues letter to Pfizer’s Board of Directors

Pfizer: Starboard Value issues letter to Pfizer’s Board of Directors

* "As you know, Starboard Value LP (together with its affiliates, "Starboard" or "we") is a large investor in Pfizer Inc. ("Pfizer" or the "Company"). As a significant shareholder, we care deeply about the Company and are committed to working constructively with management and the Board of Directors (the "Board") in order to create value for the benefit of all shareholders. As you are aware, we are scheduled to meet with Dr. Bourla, Mr. Narayen, and possibly other members of the Board on October 16, 2024, to present our views and discuss the best path forward for Pfizer."

* "As has been reported in recent press articles, Starboard approached the Company's former Chief Executive Officer Ian Read and former Chief Financial Officer Frank D'Amelio during our diligence process. During these meetings both Mr. Read and Mr. D'Amelio expressed concerns about the trajectory of the business. As former Company executives and significant individual shareholders with a deep appreciation for Pfizer's customers, employees, and shareholders, Mr. Read and Mr. D'Amelio shared our desire to see Pfizer pursue a better path forward. Therefore, they offered to be of assistance. Let us be abundantly clear, this is the extent of our engagement with Mr. Read and Mr. D'Amelio and is entirely consistent with the public reporting to date. Unfortunately, recent events have been brought to our attention. Given the gravity of these events, and our optimistic belief that the Board may not have been consulted, we believe it important to share them in writing with the Board. Specifically, we understand that people within Pfizer and/or their representatives have contacted Mr. Read and Mr. D'Amelio and purportedly threatened to commence costly litigation against them, claw back prior compensation, and cancel unvested performance stock units, unless they publicly release a statement supporting the current Chief Executive Officer, Dr. Albert Bourla."

* "While we cannot be certain that the Board did not authorize this behavior, we sincerely hope that all, or at least some, members of the Board were wholly unaware of this coercive conduct, which in our view constitutes a clear breach of fiduciary duty. Therefore, we ask the Board, as representatives of all shareholders, to immediately establish a special committee of Board members with clean hands to investigate the extent of this behavior, determine who approved and executed such conduct, and promptly hold the responsible parties accountable. To be clear, we believe this behavior is highly inappropriate, flagrantly unethical, and a significant breach of fiduciary obligations. While we are deeply troubled by this unfortunate series of events, we do hope to have a constructive engagement with the Company and look forward to meeting in-person this following Wednesday as scheduled."

>>> Birkenstock Holding Plc: 'Buckle up' for growth; initiating coverage at Buy

Birkenstock Holding Plc: 'Buckle up' for growth; initiating coverage at Buy and a $60 PT -- BTIG Research

BTIG's Janine Stichter offered, "BIRK stands out as a unique retail growth story that marries a long brand legacy with future expansion potential, capable of delivering strong DD% top-line growth (long-term algo calls for mid-to-high teens) with stable to improving margins. In our view, this level of robust yet relatively predictable growth should command a premium multiple. However, given recent noise around slower DTC performance and investor skittishness on upfront capacity investments, the shares have pulled back more than 20% off the highs, putting multiples below peers where the growth is slower and less predictable, in our view. To this end, we note several factors that remain under-appreciated, including (1) BIRK's function-led approach and strong consumer loyalty, which drives both high repeat purchases (corroborated by our own survey work) and a more stable financial profile, (2) the quality of BIRK's distribution network, which allows wholesale to serve as a key customer acquisition vehicle and a highly profitable extension of its own DTC business, and (3) the ability for recent investments (which double production capacity) to allow BIRK to realize its growth opportunities and scale globally. We initiate coverage with a Buy rating and $60 PT."

>>> US Research Calls II

Research Calls II
  • Upgrades:
    • Exxon Mobil (XOM) upgraded to Sector Outperform from Sector Perform at Scotiabank; tgt raised to $145
    • Harmony Gold (HMY) upgraded to Neutral from Underweight at JP Morgan
    • IAMGOLD (IAG) upgraded to Outperform from Sector Perform at National Bank Financial
    • L3Harris (LHX) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $300
    • LSB Industries (LXU) upgraded to Buy from Neutral at UBS; tgt raised to $11
    • Medtronic (MDT) upgraded to Outperform from Sector Perform at RBC Capital Mkts; tgt raised to $105
    • NIKE (NKE) upgraded to Buy from Hold at Truist; tgt raised to $97
    • TransUnion (TRU) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $130
    • Tronox (TROX) upgraded to Buy from Neutral at UBS; tgt raised to $19
    • Wheaton Precious Metals (WPM) upgraded to Outperform from Sector Perform at National Bank Financial
  • Downgrades:
    • BP (BP) downgraded to Sector Perform from Sector Outperform at Scotiabank
    • Centrus Energy (LEU) downgraded to Neutral from Buy at ROTH MKM; tgt raised to $62
    • Nutrien (NTR) downgraded to Neutral from Buy at UBS; tgt lowered to $51
    • PayPal (PYPL) downgraded to Mkt Perform from Outperform at Bernstein; tgt raised to $80
    • PepsiCo (PEP) downgraded to Hold from Buy at TD Cowen; tgt lowered to $183
    • Saratoga Investment (SAR) downgraded to Neutral from Buy at Ladenburg Thalmann
    • Skyworks (SWKS) downgraded to Underweight from Equal Weight at Barclays; tgt lowered to $87
  • Others:
    • MARA Holdings Inc. (MARA) initiated with an Overweight at Cantor Fitzgerald; tgt $21
    • Monday.com (MNDY) initiated with an Overweight at CapitalOne; tgt $325
    • Procter & Gamble (PG) initiated with a Neutral at DA Davidson; tgt $159
    • SiteOne Landscape Supply (SITE) initiated with a Neutral at Goldman; tgt $158
    • South State (SSB) initiated with a Neutral at Citigroup; tgt $102
    • Sunnova Energy (NOVA) initiated with a Buy at Jefferies; tgt $15
    • Synovus (SNV) initiated with a Buy at Citigroup; tgt $53
    • TXNM Energy (TXNM) initiated with a Sector Perform at Scotiabank; tgt $46
    • UMB Financial Corporation (UMBF) initiated with a Buy at Citigroup; tgt $127
    • Veracyte (VCYT) initiated with a Buy at Guggenheim; tgt $40

>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Acadia Realty Trust (AKR) upgraded to Buy from Neutral at Compass Point; tgt $27
    • Alcon (ALC) upgraded to Neutral from Sell at Redburn Atlantic
    • American Intl (AIG) upgraded to Overweight from Neutral at JP Morgan; tgt lowered to $89
    • Bank of Marin (BMRC) upgraded to Buy from Neutral at DA Davidson; tgt $24
    • Brinker (EAT) upgraded to Neutral from Underperform at BofA Securities; tgt raised to $90
    • Canadian Nat'l Rail (CNI) upgraded to Outperform from Sector Perform at RBC Capital Mkts
    • CVS Health (CVS) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $82
    • EVgo Inc. (EVGO) upgraded to Buy from Neutral at UBS; tgt raised to $8.50
    • Fortive (FTV) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $92
    • Lending Club (LC) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $15
  • Downgrades:
    • American Tower (AMT) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $230
    • Azul S.A. (AZUL) downgraded to Neutral from Buy at Seaport Research Partners
    • Cirrus Logic (CRUS) downgraded to Equal Weight from Overweight at Barclays; tgt lowered to $120
    • First Advantage Corp. (FA) downgraded to Peer Perform from Outperform at Wolfe Research
    • Hexcel (HXL) downgraded to Hold from Buy at Vertical Research; tgt $65
    • Honeywell (HON) downgraded to Neutral from Overweight at JP Morgan; tgt raised to $235
    • Hubbell (HUBB) downgraded to Neutral from Overweight at JP Morgan; tgt raised to $454
    • Huntington Ingalls (HII) downgraded to Hold from Buy at Vertical Research; tgt $275
    • Huntington Ingalls (HII) downgraded to Peer Perform from Outperform at Wolfe Research
  • Others:
    • Align Tech (ALGN) initiated with a Hold at Needham
    • Banc of California (BANC) initiated with a Neutral at Citigroup; tgt $15
    • Birkenstock Holding Plc (BIRK) initiated with a Buy at BTIG Research; tgt $60
    • Builders FirstSource (BLDR) initiated with a Buy at Goldman; tgt $225
    • Cabaletta Bio (CABA) initiated with a Buy at UBS; tgt $10
    • Carrier Global (CARR) resumed with a Neutral from Underweight at JP Morgan; tgt raised to $83
    • IperionX (IPX) initiated with a Buy at B. Riley Securities; tgt $30
    • Kyverna Therapeutics (KYTX) initiated with a Buy at UBS; tgt $13

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • TXG -25.8% (guides Q3 revs below consensus), ETWO -21.8%, INDV -17.1% (Q3 guidance), DAL -5.3%, APLD -2.7%, BKE -1.4% (Sep comps)
Other news:
  • IMTX -14.1% (announces updated phase 1b clinical data on ACTengine IMA203 TCR-T targeting PRAME in melanoma patients and provides update on upcoming SUPRAME Phase 3 Trial; announces proposed $150 mln public offering)
  • APAM -4.2% (reports Sept AUM)
  • BIPC -1.5% (Brookfield Infrastructure (BIP) announces reorganization of Brookfield Infrastructure Corporation)
  • PFE -1.3% (issues statement from Former Pfizer CEO Ian Read and Former Pfizer CFO Frank D'Amelio regarding Starboard Value)
  • BNS -0.8% (files $50 bln mixed shelf securities offering)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • TFPM +6.7% (Q3 revs and production), DPZ +2.4%, TLRY +0.6%, NEOG +0.5%
Other news:
  • TPST +33% (announces agreement with Roche (RHHBY) to support advancement of Amezalpat combination therapy into first-line hepatocellular carcinoma pivotal trial)
  • EXAI +5.8% (Exscientia plc and Recursion Pharmaceuticals (RXRX) file definitive joint proxy statement in connection with shareholder meetings on November 12)
  • AVNT +5% (raises annual dividend by 5%)
  • MGTX +3.4% (announces poster presentation on MC4R Genetic Deficiency)
  • SYM +2.5% (has entered into commercial agreements with Walmart de México y Centroamérica to implement Symbotic's industry-leading warehouse automation systems in two of the retailer's locations near Mexico City)
  • BWLP +2.1% (provides update on co's Product Services Q3 segment performance)
  • GEL +2.1% (increases common stock distribution to $0.165/share from $0.15/share)
  • MPTI +1.6% (names new CFO, also provides guidance)
  • CNM +1.3% (to acquire Eastcom Associates; also to acquire ARGCO Northeast)
  • TSLA +1.2% (expected to unveil its RoboTaxi at an event at 9 PM ET tonight)

WWD : Arnault Family Poised to Buy Majority Stake in Paris Soccer Club

Arnault Family Poised to Buy Majority Stake in Paris Soccer Club
The acquisition would set the stage for a face-off between two soccer clubs owned by rival French luxury groups.

The French capital’s soccer scene is about to heat up, amid reports that luxury magnate Bernard Arnault’s family holding is poised to buy a majority stake in Paris FC, the second-divison club that lives in the shadow of Paris Saint-Germain.

The Arnault family’s holding group Agache is set to acquire a 55 percent stake in the football club in partnership with energy drink maker Red Bull, which would buy 15 percent, according to sources with knowledge of the deal. Paris FC president and majority shareholder Pierre Ferracci would retain 30 percent.

Red Bull, which owns the Formula 1 team Oracle Red Bull Racing, said on Wednesday it has appointed German football legend Jürgen Klopp as global head of soccer, overseeing its international network of clubs including Leipzig, Salzburg and the New York Red Bulls.

The Paris FC acquisition, expected to be announced next week, will mark the Arnault clan’s latest expansion into sports, following luxury conglomerate LVMH Moët Hennessy Louis Vuitton’s sponsorship of the Paris Olympics and its recently-announced 10-year partnership with the Formula 1 racing championship.

French sports daily L’Equipe broke the news late on Wednesday that Antoine Arnault, the group’s head of communication, image and environment, and a keen soccer fan, had engineered the deal alongside his brother Frédéric Arnault, chief executive officer of LVMH Watches and managing director of Agache. LVMH declined to comment.

It sets the stage for a challenge to the supremacy of PSG, owned by Qatar Sports Investments, which regularly tops the French league.

There is another interesting dimension to the deal: Kering founder François Pinault owns the Stade Rennais football club in Brittany. If Paris FC breaks into the first division, both clubs could face off on the pitch, laying the ground for another showdown between the two historic luxury sector rivals.